title: [Experience in treating metabolic osteopathies with 1 alpha-hydroxyvitamin D3 (oksidevit)].
abstract: The action of 1 alpha-hydroxycholecalciferol (oxydevit) was estimated in 204 patients with renal osteodystrophy, osteoporosis of varying etiology, osteomalacia because of malabsorption, congenital rickets-like diseases. The drug was shown to be highly effective in the treatment of secondary hyperparathyroidism in uremia, steroidal and senile osteoporosis. The treatment involved replacement therapy.
authors.forename: D A
authors.initials: DA
authors.lastname: Babarykin
authors.forename: N A
authors.initials: NA
authors.lastname: Reĭsner
authors.forename: A N
authors.initials: AN
authors.lastname: Riabukha
authors.forename: R L
authors.initials: RL
authors.lastname: Rozental'
mesh_terms: D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D010018:Osteomalacia / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism; D012279:Rickets / Q000151:congenital / Q000188:drug therapy / Q000378:metabolism
chemical_list: D006887:Hydroxycholecalciferols; C008088:alfacalcidol
vernacular_title: Opyt lecheniia metabolicheskikh osteopatiĭ 1 al'fa-gidroksivitaminom D3 (oksidevitom).